ADJUNCT CLINICAL PAPER

Real-Time Clinical Decision Making at 71:

AI-Assisted Health Optimization as a Continuous Feedback Loop

Mark A. Skoda

In collaboration with Claude (Anthropic)

Validated in partnership with Vanderbilt University Medical Center

March 2026

An adjunct to:

"Reversing Biological Age at 71: A 150-Day Protocol-Driven Metabolic Transformation"

MarkSkoda.com | mark@markskoda.com

Abstract

The original case study documented a 150-day transformation in a 71-year-old male with a history of acute pancreatitis and insulin-dependent type 2 diabetes, achieving insulin independence, A1C reduction from 7.4% to 6.0%, and an estimated 58-pound weight loss through a structured six-pillar protocol validated by Vanderbilt University Medical Center.

This adjunct paper documents the next phase of that transformation, focusing not on what was achieved but on how a continuous AI-assisted feedback loop compresses the traditional clinical reaction cycle from months to hours. Using three simultaneous clinical data sources — a 57-biomarker blood panel (SiPhox Health, March 16, 2026), a DEXA body composition scan (Live Lean Nashville, March 23, 2026), and a Resting Metabolic Rate assessment (March 23, 2026) — this paper documents the identification of residual risk factors, the real-time protocol adjustments made within 24 hours of data receipt, and the integrated monitoring architecture now in place for a 90-day validation cycle concluding June 15, 2026.

The central thesis is this: the value of precision health monitoring is not the data itself — it is the speed and accuracy of the decisions the data enables. When a 71-year-old with a compromised metabolic history can identify an atherogenic lipid phenotype, initiate pharmacological intervention, redesign his exercise protocol for visceral fat targeting, resolve a supplement contraindication, and schedule a therapeutic blood donation — all within 24 hours of receiving clinical data — that represents a fundamentally different model of aging medicine than the current standard of annual physicals and 6-month follow-up appointments.

The AI layer is not one of six pillars. It is the connective tissue that makes all six pillars function as a continuously optimizing integrated system.

Section 1: Where the Original Case Study Left Off

The baseline established in the original case study (July 2025) represents the clinical starting point against which all subsequent data must be measured:

Baseline Marker	July 2025 (Start)	Status
Body Weight	265 lbs	Baseline
Body Fat %	~35%	Baseline
HbA1c	7.4%	Diabetic range
Insulin Status	Insulin dependent	Active prescription
Estimated Biological Age	75-80 years	Above chronological
Fasting Glucose	~140-160 mg/dL	Uncontrolled
Energy / Functional Status	Severely limited	Pre-transformation

By the conclusion of the original 150-day documented protocol, the following outcomes were achieved and validated:

- Insulin independence achieved — prescription discontinued
- A1C reduced from 7.4% to 6.0% — moved from diabetic to borderline prediabetic range
- Estimated 40-pound weight loss documented in the original manuscript
- Biological age estimated at 55-58 years — a defensible 17-22 year reversal from baseline
- Continuous glucose monitoring established as a daily protocol tool
- Six-pillar protocol validated by Vanderbilt University Medical Center physician team

The original case study documented what was possible. This adjunct documents what happens next — when the monitoring infrastructure is maintained, the data continues to accumulate, and AI-assisted analysis keeps the protocol continuously calibrated.

Section 2: New Clinical Data — March 2026 Comprehensive Assessment

On March 16 and March 23, 2026, a comprehensive three-source clinical assessment was completed — the most thorough single evaluation since the original case study baseline. The three data sources provide complementary views of the same underlying physiology.

2.1 SiPhox 57-Biomarker Blood Panel — March 16, 2026

The SiPhox panel provides biochemical visibility across cardiovascular, metabolic, hormonal, and nutritional domains simultaneously. Key findings organized by clinical priority:

Cardiovascular — Primary Risk Cluster

Marker	Result	Optimal Range	Status
Apolipoprotein B (ApoB)	132 mg/dL	40-70 mg/dL	Above all ranges
Total Cholesterol	264 mg/dL	160-200 mg/dL	Above all ranges
LDL Cholesterol (calc)	160 mg/dL	40-90 mg/dL	Above good range
Triglycerides	160 mg/dL	40-70 mg/dL	Above all ranges
LDL-C:ApoB Ratio	1.21	1.5-2.0	Below optimal — small dense LDL
VLDL Cholesterol	32 mg/dL	5-15 mg/dL	Elevated
Triglycerides:HDL Ratio	2.22	0-1.1	Above good range
HDL Cholesterol	72 mg/dL	>60 mg/dL	Good
ApoB:ApoA1 Ratio	0.64	0-0.7	Optimal

Clinical Interpretation — Lipid Phenotype

The LDL-C:ApoB ratio of 1.21 against an optimal range of 1.5-2.0 is the most clinically significant finding in this panel. When this ratio is depressed, it indicates that LDL particles are small and dense rather than large and buoyant. Small dense LDL is the most atherogenic lipoprotein phenotype — it penetrates arterial walls more easily, oxidizes more readily, and drives plaque formation more aggressively than equivalent LDL mass in large buoyant particles. This phenotype is the biochemical signature of insulin resistance and metabolic syndrome, consistent with the subject's history. Combined with ApoB at 132 — the actual count of atherogenic particles — and triglycerides at 160 indicating excess VLDL production, this is a cardiovascular risk profile requiring immediate pharmacological intervention.

Metabolic — Active Monitoring Required

Marker	Result	Prior Result	Trend
HbA1c	6.2%	6.0% (Dec 2025)	Increased 0.2%
Estimated Average Glucose (eAG)	131.24 mg/dL	125.49 mg/dL	Increased
Morning Cortisol	23.4 ug/dL	N/A (first measure)	Above good range
C-Peptide	0.94 ng/mL	N/A	Low normal — pancreatic history
hsCRP	1.06 mg/L	N/A	Borderline — inflammation present
Testosterone:Cortisol Ratio	0.026	0.04-0.08 optimal	Below optimal
eGFR	82 mL/min	N/A	Below good range of 90
Ferritin	222.8 ng/mL	N/A	Elevated — optimal 50-150

Clinical Interpretation — The Cortisol Connection

The A1C drift from 6.0% to 6.2% and the eAG increase from 125.49 to 131.24 mg/dL appear to be cortisol-mediated rather than diet-driven. Morning cortisol at 23.4 ug/dL significantly exceeds the good range ceiling of 17 ug/dL. Elevated cortisol drives hepatic gluconeogenesis — the liver releases stored glucose in response to the cortisol signal regardless of dietary intake. This mechanism explains why glucose control deteriorated despite consistent protocol adherence during the same period. The restaurant launch of Sideline Smokehouse and Tap in early 2026 represents the most probable root cause of the cortisol elevation, which then cascades into glucose dysregulation and the suppressed testosterone:cortisol ratio.

Hormonal — Notable Strengths

Marker	Result	Range	Status
Testosterone, Total	624.38 ng/dL	420-750 optimal	Optimal
Free Testosterone	8.81 ng/dL	8-26 optimal	Optimal
DHEA-S	166.4 ug/dL	64.5-175 optimal	Good
Vitamin D (25-OH)	72.8 ng/mL	40-70 optimal	Well optimized
PSA	0.4 ng/mL	0-3 optimal	Stable
TSH	0.9 uIU/mL	1-2 optimal	Slightly below optimal

Total testosterone at 624 ng/dL in the optimal range at age 71 is a meaningful clinical asset. The resistance training protocol is directly contributing to testosterone maintenance. The suppressed testosterone:cortisol ratio (0.026 vs 0.04-0.08 optimal) is not due to low testosterone but to excessive cortisol — the numerator is healthy, the denominator is the problem.

2.2 DEXA Body Composition Analysis — March 23, 2026

The DEXA scan at Live Lean Nashville on March 23, 2026 provides the gold-standard body composition baseline — the clinical truth against which all subsequent bioimpedance measurements will be calibrated.

Total Body Composition

Metric	Value	Context
Total Mass (scale weight)	212.8 lbs	DEXA measurement (includes water, bone, tissue)
Total Fat Mass	64.1 lbs	30.1% of total mass
Total Lean Mass	140.8 lbs	Preserved through 58 lb weight loss
Bone Mineral Content	7.9 lbs	3.7% of total — within normal range
Fat-Free Mass	148.7 lbs	Lean + BMC
Body Fat Percentage	30.1%	Reduced from estimated ~35% at baseline

Regional Body Composition

Region	Fat %	Fat Mass	Lean Mass	Clinical Note
Arms	25.7%	6.6 lbs	18.0 lbs	Lean — resistance training visible
Legs	26.7%	17.9 lbs	46.1 lbs	Well developed — good symmetry

Region	Fat %	Fat Mass	Lean Mass	Clinical Note
Trunk	34.4%	37.1 lbs	68.3 lbs	Primary fat reduction target
Android (abdomen)	37.3%	6.1 lbs	10.0 lbs	Highest regional fat % — VAT site
Gynoid (hips)	30.0%	8.7 lbs	19.4 lbs	Moderate — A/G ratio 1.22
Total	30.1%	64.1 lbs	140.8 lbs	

Visceral Adipose Tissue (VAT)

Metric	Value	Threshold	Status
VAT Volume	135.86 in³	112.10 in³ (At Risk threshold)	21% above At Risk threshold
VAT Fat Mass	4.63 lbs	N/A	Deep visceral fat — not visible externally
Android:Gynoid Ratio	1.22	<1.0 optimal	Central adiposity pattern confirmed

> **Clinical Significance of VAT**
> *Visceral adipose tissue is metabolically active fat stored around abdominal organs — the liver, pancreas, kidneys, and intestines. Unlike subcutaneous fat (which sits under the skin and is primarily cosmetic), VAT secretes inflammatory cytokines, disrupts insulin signaling, and drives the lipid phenotype seen in the blood panel. The subject's VAT volume of 135.86 in³ places him 21% above the "At Risk" threshold. Critically, this VAT burden is not externally visible — the body composition photographs show a relatively lean abdominal profile because the fat is internal. The disconnect between visual appearance and DEXA-measured VAT is precisely why DEXA is a superior clinical tool compared to visual assessment or BMI. Reducing VAT to below 112 in³ is the single most impactful body composition target for the next 90-day cycle.*

Bone Density — Exceptional Finding

Metric	Value	Interpretation
Total Body BMD	1.445 g/cm²	Well above age-expected values
YA T-Score	+2.4	2.4 standard deviations above young adult mean
AM Z-Score	+2.9	2.9 standard deviations above age-matched mean

A T-score of +2.4 and Z-score of +2.9 at age 71 is clinically exceptional. The normal range for a 71-year-old male is typically 0 to -1.0. The resistance training protocol — specifically the progressive overload compound movements — is the primary driver of this bone density maintenance. This finding has significant long-term implications for fracture risk, functional independence, and overall healthspan.

Muscle Symmetry Analysis

The DEXA muscle balance assessment shows excellent bilateral symmetry — right arm 9.2 lbs vs left arm 8.8 lbs (0.4 lb difference, within the 0.5 lb normal threshold); right leg 22.7 lbs vs left leg 23.3 lbs (0.6 lb difference, within the 1.5 lb normal threshold). This symmetry reflects consistent bilateral training and is important for functional movement efficiency and injury prevention.

2.3 Resting Metabolic Rate Assessment — March 23, 2026

Metric	Value	Context
Resting Metabolic Rate (RMR)	2,269 kcal/day	Faster than age/weight-matched peers
Maintenance Calories	2,800 kcal/day	Before measured exercise
Weight Loss Target Calories	2,270 kcal/day	Before measured exercise
Exercise Add-Back	75% of measured exercise calories	Protocol recommendation
Protein Target	140-210 grams/day	Per day for lean mass preservation
BMI at Assessment	27.24	Overweight classification

Clinical Significance of RMR Finding

An RMR of 2,269 kcal/day running faster than age- and weight-matched peers is a critical finding. The most common failure mode in extended weight loss protocols is metabolic adaptation — the body reduces its resting energy expenditure in response to caloric restriction and weight loss, making further fat loss progressively more difficult. This RMR result confirms that the protocol has avoided metabolic adaptation. The preserved lean mass (140.8 lbs) is the primary driver: muscle tissue is metabolically expensive to maintain, and the resistance training plus protein protocol has kept the metabolic engine running efficiently through a 58-pound weight loss. This is the physiological foundation that makes continued fat loss sustainable without further caloric restriction.

Section 3: The Feedback Loop in Action — 24-Hour Protocol Response

The following sequence documents the protocol adjustments made within 24 hours of receiving the March 16-23 clinical data. This sequence is the empirical demonstration of the paper's central thesis.

3.1 The Traditional Clinical Model — for Comparison

Under the standard model of care for a 71-year-old male with this blood panel, the typical sequence would be:

- Physician reviews lab results at next available appointment — typically 4-6 weeks later
- Statin prescription called in — patient picks up within 3-7 days
- Lifestyle modification advice provided verbally — diet and exercise
- Follow-up lipid panel ordered — scheduled 3-6 months out
- No real-time monitoring of glucose, cortisol, or metabolic response
- No specific VAT-targeted exercise protocol designed
- No supplement contraindication review conducted
- Total elapsed time from data to meaningful action: 4-8 weeks minimum

3.2 The AI-Assisted Continuous Feedback Model — What Actually Happened

The following actions were taken within 24 hours of the clinical data being reviewed:

Hour	Action	Data Trigger	Outcome
0-2	ApoB and LDL-C:ApoB ratio analyzed	SiPhox panel — ApoB 132, ratio 1.21	Small dense LDL phenotype identified
2-4	VAT volume context established	DEXA — 135.86 in³, 21% above At Risk	Primary body composition target defined
4-6	Zone 2 cardio protocol designed for VAT	DEXA + exercise physiology literature	5% incline, 108-110 bpm, 30 min daily
6-8	Pravastatin 40mg initiated	ApoB 132, LDL 160, physician prescription	Statin therapy commenced same day
8-10	Red Yeast Rice contraindication flagged	RYR + statin = dual statin mechanism	RYR removed from stack — pharmacist confirmed
10-12	Citrus Bergamot 1,200mg added	Complementary LDL/triglyceride agent	Adjunct lipid support initiated
12-16	Blood donation scheduled	Ferritin 222.8 — elevated above 150	Ferritin reduction intervention planned
16-20	72-hour fast initiated	A1C drift + cortisol elevation pattern	Glucose baseline reset protocol begun
20-24	Zone 2 workout executed fasted	VAT protocol + fast synergy	Full 60 min zone 2 during fast documented
24+	Renpho 8-electrode scale ordered	Daily tracking gap identified	Daily body composition calibrated to DEXA

The Speed Advantage Quantified

From data receipt to first pharmacological intervention: less than 12 hours. From data receipt to complete protocol restructuring: less than 24 hours. From data receipt to therapeutic blood donation scheduled: less than 24 hours. The traditional model would achieve the same set of interventions in 4-8 weeks at best. The AI-assisted model compressed this to a single day — not because the interventions were rushed, but because the data interpretation, contraindication analysis, protocol design, and decision support were available instantly rather than waiting for a scheduled appointment.

Section 4: Dexcom as Real-Time Metabolic Intelligence

The Dexcom continuous glucose monitor is the highest-frequency data source in the monitoring stack — providing a reading every 5 minutes, 24 hours a day. During the 72-hour fast initiated March 25, 2026, the CGM trace documented multiple distinct physiological phenomena in real time, each of which informed a protocol decision.

4.1 The 72-Hour Fast — CGM Data Log

Time	Reading	Arrow	Phenomenon	Protocol Decision
Mon 18:40	188 mg/dL	Flat	Post-Italian dinner peak	Began 72-hour fast — water only
Mon 19:43	129 mg/dL	Down	Rapid post-prandial clearance	Fast confirmed — glucose clearing well
Tue 07:33	138 mg/dL	Flat	Dawn phenomenon — cortisol surge	Cortisol-glucose link documented
Tue 11:17	119 mg/dL	Flat	Morning fast deepening	Approaching fat oxidation transition
Tue 15:30	153 mg/dL	Flat	Post-workout cortisol response	Workout cortisol mechanism identified
Tue 16:10	164 mg/dL	Flat	Peak cortisol response	Protocol note: no heavy resistance on fast days
Tue 16:57	145 mg/dL	Flat	Cortisol clearing	Confirmed peak had passed
Tue 17:14	125 mg/dL	Down	Active cortisol clearance	Fast reasserting control
Tue 18:20	119 mg/dL	Flat	Stabilized — cortisol resolved	Hour 25 — clean fasting state
Wed 19:55	133 mg/dL	Flat	Strategic refeed response	Cottage cheese + oranges pre-donation

4.2 Key Patterns Documented

Dawn Phenomenon

The 138 mg/dL reading at 07:33 on Tuesday — after 14 hours of fasting — demonstrates classic dawn phenomenon: cortisol and growth hormone secreted in the early morning trigger hepatic gluconeogenesis, releasing stored glucose into the bloodstream. This occurred without any food intake. The magnitude of this response (138 mg/dL while fasted) is consistent with the elevated morning cortisol of 23.4 ug/dL measured in the SiPhox panel, providing a mechanistic link between the blood panel finding and the CGM behavior.

Exercise-Induced Cortisol Spike During Fasting

The glucose rise from 119 mg/dL at 11:17 to a peak of 164 mg/dL by 16:10 — during a fasted resistance training session — documents the cortisol spike produced by heavy exercise during extended fasting. When both fasting stress and exercise stress are present simultaneously, cortisol production is additive. The glucose peak of 164 mg/dL with no food intake is entirely cortisol-driven gluconeogenesis. This data generated an immediate protocol adjustment: heavy resistance training sessions are reserved for fed days. Fasted workout days are zone 2 cardio only.

Strategic Refeed at Hour 50

At hour 50 of the fast, a strategic refeed of cottage cheese and two oranges (approximately 250-300 calories, 15-20g protein, 30-35g natural carbohydrate) was consumed. The rationale was twofold: lean mass preservation through the final 14 hours of the fast, and pre-donation fuel for a scheduled therapeutic blood donation the following morning. The CGM response — 133 mg/dL with a flat arrow 45 minutes after eating, already declining — confirmed a controlled response. This is notably restrained for a subject with reduced insulin production from the 2017 pancreatitis event.

Section 5: The Cortisol Problem — Connecting the Data Dots

One of the most important functions of AI-assisted data synthesis is the ability to connect findings across data streams that clinicians typically review in isolation. The cortisol problem in this case illustrates this clearly.

5.1 The Evidence Chain

Data Source	Finding	Cortisol Connection
SiPhox Blood Panel	Morning cortisol 23.4 ug/dL (good range ceiling: 17)	Direct measure — elevated baseline
SiPhox Blood Panel	A1C 6.2% — up from 6.0% December 2025	Cortisol drives hepatic gluconeogenesis → chronic glucose elevation
Dexcom Clarity	30-day GMI 6.6% — higher than blood panel A1C of 6.2%	Sustained cortisol elevation throughout monitoring period

Data Source	Finding	Cortisol Connection
Dexcom CGM	Dawn phenomenon 138 mg/dL while fasted	Morning cortisol surge producing glucose without food intake
Dexcom CGM	Exercise glucose spike to 164 mg/dL while fasted	Exercise cortisol additive to fasting cortisol — no food involved
SiPhox Blood Panel	Testosterone:Cortisol ratio 0.026 (optimal 0.04-0.08)	Cortisol suppressing anabolic effect of healthy testosterone
Clinical Context	Sideline Smokehouse and Tap launched early 2026	Operational stress load as primary cortisol driver

Synthesis — What No Single Data Source Would Show Alone

No single data source tells this story. The blood panel shows elevated cortisol and A1C. The CGM shows dawn phenomenon and exercise spikes. The clinical context provides the stress load explanation. Only when all three are synthesized together does the mechanism become clear: the restaurant launch created a sustained cortisol elevation that suppressed the testosterone:cortisol ratio, drove hepatic gluconeogenesis responsible for the A1C drift, and produced the glucose patterns visible on the CGM trace. The intervention is not primarily dietary — it is cortisol management through operational stress reduction, phosphatidylserine supplementation, and sleep architecture protection. This is the kind of cross-domain synthesis that AI-assisted analysis enables and that traditional siloed clinical review misses.

5.2 Cortisol Management Protocol

- Phosphatidylserine 400-600mg daily — blunts cortisol response with solid clinical evidence
- Magnesium glycinate 400mg nightly — supports cortisol regulation and sleep quality
- Zone 2 cardio only on fasted days — eliminates additive cortisol load
- Heavy resistance sessions on fed days only — prevents cortisol spike compounding
- Sleep architecture protection — minimum 7 hours, consistent schedule
- Operational stress audit — identify and delegate highest-cortisol restaurant tasks

---

Section 6: Exercise Protocol Evolution — Zone 2 as a Clinical Intervention

The addition of structured zone 2 cardio to the existing resistance training protocol represents a direct clinical response to the DEXA VAT finding. This is not a general fitness recommendation — it is a targeted metabolic intervention designed for a specific clinical problem.

6.1 The Physiological Rationale for Zone 2 and VAT

Visceral adipose tissue is preferentially mobilized during sustained low-intensity aerobic exercise for several interconnected reasons:

- At zone 2 intensity (approximately 60-70% of maximum heart rate), fat oxidation is the primary fuel source. The body draws on stored triglycerides — including those in visceral fat deposits — rather than glucose or glycogen.
- Zone 2 work does not significantly elevate cortisol. Higher intensity exercise (zone 4-5) produces a cortisol response that can actually promote visceral fat storage through the cortisol-insulin interaction. Zone 2 avoids this counterproductive mechanism.
- During a fasted state, zone 2 exercise is particularly effective for VAT reduction because glycogen stores are partially depleted, pushing the body toward fat oxidation earlier in the session.
- The 30-minute minimum at zone 2 is the threshold at which fat oxidation becomes the dominant fuel pathway for most metabolically healthy individuals. The subject's metabolic history may require the full 30 minutes before this transition is complete.

6.2 Protocol Specification

Parameter	Specification	Rationale
Duration	30-35 minutes	Minimum threshold for sustained fat oxidation
Incline	5% grade	Increases caloric expenditure while maintaining low impact on joints
Heart Rate Target	108-110 bpm	Zone 2 for subject's current cardiovascular conditioning
Frequency	Daily — including resistance training days	Cumulative VAT reduction effect; zone 2 does not impair resistance recovery
Fasted vs Fed	Zone 2 only when fasted	Avoids additive cortisol spike from heavy resistance + fasting combination
Resistance Training Days	Zone 2 maintained throughout full resistance session	Full 60+ minutes of zone 2 on compound training days

6.3 First Protocol Execution — March 25, 2026

The first full zone 2 protocol was executed at hour 20 of the 72-hour fast on March 25, 2026. The session consisted of 31 minutes on the treadmill at 5% incline followed by a full barbell and machine resistance circuit — heart rate maintained at 108-110 bpm throughout the entire 60+ minute session. Dexcom data documented the cortisol response in real time, providing the feedback that generated the fasted-day protocol adjustment (zone 2 cardio only during extended fasts). The session itself represented full execution of the new VAT-targeting protocol.

Section 7: The Monitoring Stack — Daily, Monthly, Quarterly

The monitoring architecture now in place represents a multi-layer continuous feedback system with no significant gaps between clinical data points.

Frequency	Tool	Primary Metrics	Clinical Role
Continuous (5 min)	Dexcom CGM	Glucose, trends, time-in-range	Real-time metabolic state and cortisol proxy
Daily	Renpho 8-Electrode Scale	Weight, body fat %, lean mass, visceral fat estimate	Trend tracking between DEXA scans
Daily	Subjective logging	Energy, sleep quality, workout performance	Protocol adherence and recovery context
Monthly	SiPhox Blood Panel	57 biomarkers — lipids, metabolic, hormonal	Rapid pharmacological response detection
Quarterly	DEXA Scan (Live Lean)	Body composition, VAT volume, bone density	Gold standard body composition — Renpho calibration anchor
Quarterly	SiPhox Full Panel	Aligned with DEXA cycle	Complete biochemical snapshot with DEXA context
Quarterly	RMR Assessment	As needed — established baseline now in place	Metabolic adaptation monitoring

7.1 The Renpho Calibration Protocol

The Renpho 8-electrode bioimpedance scale, ordered March 25, 2026, provides daily body composition estimates between DEXA scans. Bioimpedance accuracy is limited by hydration state and measurement conditions, but its value is in trend tracking rather than absolute precision. The calibration protocol:

- First measurement taken Saturday morning, March 28, 2026 — fasted, post-void, pre-water, pre-workout
- Renpho body fat % compared against DEXA result of 30.1% from March 23 — offset calculated
- All subsequent Renpho readings adjusted by the measured offset
- DEXA on June 15, 2026 recalibrates the offset for the following 90-day cycle
- Measurement protocol identical every day: same time, same conditions, same clothing (none)

This calibration approach converts a consumer device into a legitimate clinical tracking tool — one that provides daily feedback on the trajectory of fat loss and lean mass preservation between quarterly DEXA gold-standard measurements.

Section 8: AI as the Connective Tissue

In the original case study, AI-assisted optimization was documented as Pillar 6 of the six-pillar protocol. This framing, while accurate for the initial phase, understates the role AI plays in the mature protocol. AI is not one of six pillars — it is the connective tissue that makes all six pillars function as a continuously optimizing integrated system.

8.1 What AI Does That No Single Clinician Can

- Simultaneous cross-domain synthesis: lipid data, glucose data, body composition data, exercise physiology, supplement pharmacology, and cortisol-glucose mechanisms analyzed together in real time — not in separate specialty appointments scheduled weeks apart
- Contraindication identification across self-selected supplement stacks: the Red Yeast Rice / pravastatin interaction was identified immediately because the AI maintained context across the full supplement protocol and the newly prescribed medication simultaneously
- Protocol translation: DEXA data showing VAT at 135.86 in^3 was immediately translated into a specific exercise prescription (30 minutes, 5% incline, 108-110 bpm) based on exercise physiology principles — in minutes rather than the weeks it would take to receive a referral to an exercise physiologist
- Real-time CGM interpretation: each glucose reading was interpreted not in isolation but in the context of fasting hours, prior readings, cortisol baseline, exercise timing, and food intake — generating clinical decisions from raw numbers that would otherwise require a specialist to review
- Longitudinal memory across data streams: connecting the December 2025 A1C of 6.0% to the March 2026 reading of 6.2% to the cortisol elevation to the restaurant launch timeline — a pattern that would only be visible to a clinician who reviewed notes across multiple appointments over six months

8.2 The Speed Differential — A Clinical Argument

The argument for AI-assisted health optimization is not that it replaces clinical care. It is that it eliminates the latency between data and action that currently defines the standard of care for aging adults.

A 71-year-old male with an atherogenic lipid phenotype, elevated cortisol, and visceral fat in the at-risk category is accumulating cardiovascular risk every day the appropriate interventions are delayed. The traditional model introduces 4-8 weeks of latency between data and action as a structural feature of how clinical care is delivered. The AI-assisted model reduces this to hours.

Over a 10-year period, the cumulative difference between a model that responds in hours and one that responds in weeks — across hundreds of individual data points and protocol decisions — is not marginal. It is the difference between managed disease progression and genuine healthspan extension.

Section 9: 90-Day Targets — June 15, 2026

Section 10: Implications for Clinical Practice and Aging Medicine

This case documents a single individual. But the model it demonstrates has implications that extend beyond the individual case.

10.1 The Democratization of Precision Medicine

The monitoring tools used in this protocol — continuous glucose monitor, at-home blood panel, DEXA scan, resting metabolic rate assessment, bioimpedance scale — were not available to the general public at meaningful scale even five years ago. Today they are accessible to any motivated individual:

- Dexcom CGM: available by prescription, covered by Medicare Part B for eligible diabetic patients
- SiPhox at-home blood panel: 57 biomarkers at a consumer price point, results in days
- DEXA scan: $72-150 at commercial providers without a physician referral in most states
- RMR assessment: $88-150 at commercial metabolic testing providers
- Renpho 8-electrode scale: $175, consumer purchase, daily body composition tracking

The total annual cost of this monitoring stack — approximately $1,500-2,000 per year — is less than a single emergency room visit and a fraction of the cost of the complications that inadequate monitoring allows to develop silently.

10.2 The Case for Continuous Monitoring as Standard of Care

The standard of care for a 71-year-old with type 2 diabetes and cardiovascular risk factors is approximately two physician visits per year with one or two blood panels. This produces data at a frequency that is structurally incapable of detecting the kind of patterns documented in this case:

- The cortisol-driven A1C drift from 6.0% to 6.2% over three months — visible only with quarterly monitoring
- The dawn phenomenon glucose pattern — visible only with continuous CGM data
- The workout cortisol spike mechanism — visible only with real-time CGM during exercise
- The VAT accumulation reaching the At Risk threshold — visible only with DEXA, not detectable by BMI or visual assessment

These are not rare or exotic findings. They are the normal, expected metabolic dynamics of an aging adult with a history of metabolic disease. The fact that they are typically invisible to the clinical system is not a clinical judgment — it is a structural limitation of low-frequency monitoring.

10.3 AI as the Interpreter Layer

Consumer health monitoring tools produce data. AI provides the interpretation layer that converts data into decisions. Without interpretation, a CGM reading of 138 mg/dL while fasted is a number. With AI-assisted synthesis, it is a cortisol signal, connected to the blood panel finding, connected to the restaurant launch stress timeline, connected to a specific supplement intervention and a protocol modification for fasted exercise days.

The AI layer does not replace clinical judgment. It supplements clinical judgment by ensuring that the clinician and the patient arrive at appointments with data already synthesized, patterns already identified, and specific questions already formed. In the current model, those synthesis activities often happen in a 15-minute appointment with incomplete information. In the AI-assisted model, they happen continuously, in real time, with complete information.

Conclusion

This adjunct paper documents a model, not just a result. The result — a 71-year-old male with a history of insulin-dependent diabetes and acute pancreatitis, now 58 pounds lighter, insulin independent, with exceptional bone density, preserved lean mass, and a resting metabolism faster than age-matched peers — is compelling on its own terms.

But the more important story is the model that produced these results and continues to refine them. A monitoring stack that sees everything. An AI interpretation layer that synthesizes across data streams simultaneously. A feedback loop that reduces the latency between data and action from weeks to hours. A protocol that treats aging not as a passive process to manage but as a system to engineer.

The 90-day validation cycle concluding June 15, 2026 will document whether the specific interventions initiated in March — pravastatin, zone 2 cardio, cortisol management, therapeutic blood donation, Berberine — produced the predicted clinical outcomes. The data will be comprehensive: DEXA, SiPhox, Dexcom, and daily Renpho trend data, all calibrated against the March 2026 baseline established in this paper.

The phoenix as a symbol was chosen deliberately. The transformation documented here is not linear improvement — it is a more fundamental restructuring of what physiological aging means for this individual. The sub-200 lb milestone and the phoenix tattoo planned to mark it are not aesthetic goals. They are the visible marker of a documented biological outcome.

The clinical data will follow.

Appendix A: Active Supplement Stack — March 2026

Supplement	Dose	Timing	Primary Target
Pravastatin	40mg	Evening with food	ApoB, LDL-C, particle size
Citrus Bergamot (25:1 extract)	1,200mg	Morning	LDL, triglycerides, HDL
Berberine	500mg	With meals	Glucose, LDL (PCSK9 inhibition)
Nattokinase	Per label	Morning fasted	Blood viscosity, cardiovascular
Magnesium Glycinate	400mg	Evening	Cortisol, glucose, sleep
Vitamin D3 + K2	Per protocol	Morning with fat	Bone density (already optimal)
Omega-3 EPA/DHA	4g target	With meals	Triglycerides, inflammation
CoQ10 (standalone)	200-400mg	With pravastatin meal	Statin-depleted CoQ10 replacement

Appendix B: Exercise Protocol Specification — March 2026

Day Type	Protocol	Duration	Heart Rate Target	Notes
Fed + Resistance	Zone 2 incline + full compound resistance circuit	60-75 min	108-110 bpm throughout	Progressive overload on all compound movements
Fed + Cardio only	Zone 2 incline walk	30-35 min	108-110 bpm	Active recovery or light days
Fasted	Zone 2 incline walk only	30-35 min	108-110 bpm	No heavy resistance — cortisol management
Extended fast day	Light zone 2 or rest	20-30 min max	Below 110 bpm	Listen to body — electrolytes critical

Appendix C: June 15, 2026 Assessment Protocol

- SiPhox 57-biomarker blood panel — fasted draw, morning of June 15
- DEXA scan — Live Lean Nashville — same day, afternoon
- Renpho calibration — morning of June 15, same protocol as baseline measurement
- Dexcom Clarity 30-day summary export — preceding 30 days
- Weight and body composition trend from daily Renpho log
- Supplement stack documentation — any changes from March 2026 baseline
- Exercise log summary — zone 2 sessions, resistance sessions, fasting cycles

All data to be compared directly against the March 2026 baseline established in this paper. Targets defined in Section 9.

Mark A. Skoda

MarkSkoda.com | mark@markskoda.com

Nashville, Tennessee | March 2026